Engineered Enzymes that Retain and Regenerate their Cofactors Enable Continuous-Flow Biocatalysis

Carol J. Hartley¹, Charlotte C. Williams², Judith A. Scoble², Quentin I. Churches², Andrea North², Nigel G. French¹, Tom Nebl², Greg Coia², Andrew C. Warden¹, Greg Simpson³, Andrew R. Frazer³, Chantel Nixon Jensen⁴, Nicholas J. Turner⁴, Colin Scott¹.

¹*Biotechnology and Synthetic Biology Group, CSIRO Land & Water, Black Mountain Science & Innovation Precinct, Canberra, Australia*

²*CSIRO Manufacturing, 343 Royal Parade, Parkville, Victoria 3052, Australia*

³*CSIRO Manufacturing, Bag 10, Bayview Avenue, Clayton, Victoria 3168, Australia*

⁴*School of Chemistry, Manchester Institute of Biotechnology, University of Manchester, UK*

Keywords: nanomachines, nanofactory, biocatalysis, continuous flow biocatalysis, synthetic biology, glycerol kinase, glycerol-3-phosphate dehydrogenase, aldolase, reactor, enzyme immobilization, D-fagomine, cofactor immobilization, cofactor recycling.

For correspondence email: colin.scott@csiro.au

Introduction

Biocatalysis is used for many chemical syntheses due to its high catalytic rates, specificities and operation under ambient conditions ^{1, 2}. Continuous-flow chemistry offers advantages to biocatalysis, avoiding process issues caused by substrate/product inhibition, equilibrium controlled limitations on yield and allosteric control ³. Modular continuous-flow biochemistry would also allow the flexible assembly of different complex multistep reactions ³⁻⁶. Here we tackle some technical challenges that currently prohibit the wide-spread use of continuous flow biocatalysis; cofactor immobilization and site-specific immobilization. We provide the first example of enzymes engineered to retain and recycle their cofactors, and the use of these enzymes in continuous production of chiral pharmaceutical intermediates.

Enzyme immobilization for continuous-flow applications has been studied for some time; indeed, a number of industrial processes are currently based on such technologies ^{4, 6-10}. However, such processes have generally been limited to cofactor-independent enzymes, such as esterases. Cofactors, such as nicotinamide adenine dinucleotide (NAD⁺) and adenosine triphosphate (ATP), are used stoichiometrically unless recycled, typically by a second enzyme: without recycling, cofactors become prohibitively expensive for most industrial syntheses. As cofactors require diffusion for recycling, they are ill-suited for use in continuous-flow reactors and the lack of a practical engineering solution for the issue has stymied the use of cofactor-dependent enzymes in continuous-flow applications ⁴; although, growing interest in immobilized biocatalysts for cell-free metabolic engineering has led to the development of a variety of enzyme-cofactor-carrier combinations ⁵.

Herein, we propose a novel and generalizable chemo-genetic enzyme engineering approach that enables the fabrication of modular, multistep, biocatalytic, continuous-flow reactors using cofactor-dependent enzymes, thereby extending the utility of biocatalysis for continuous-flow production systems and cell-free metabolic engineering ¹¹.

Results

Nanomachine design

Our design for a biocatalyst that can retain and recycle its cofactor (a ‘nanomachine’) was inspired by enzymes that retain their substrates *via* covalent attachment during a reaction cascade involving multiple active sites, e.g. phosphopantetheine-dependent synthases ¹²⁻¹⁴ and lipoic acid-dependent dehydrogenases ¹⁵. In such enzymes, the substrate is delivered from one active site to the next by a

flexible ‘swinging arm’ that is covalently attached to the protein. We have adopted a similar strategy, whereby a flexible swinging arm covalently attaches a cofactor to a synthetic, multidomain protein and delivers that cofactor to the different active sites of the fusion protein, allowing its simultaneous use and recycling, while preventing its diffusion (Figure 1).

The general design of our nanomachines is shown in Figure 1. Each nanomachine is comprised of three modules: a catalytic module that drives the desired synthesis reaction, a cofactor recycling module that regenerates the cofactor after use, and an immobilization module that allows site-specific, covalent conjugation to an activated surface. The modular design is intended to allow a small number of immobilization and cofactor recycling modules to be used with a wide variety of synthesis modules, thereby enabling diverse synthetic reactions using a relatively small library of core nanomachine components. It is envisaged that multiple nanomachines could be combined in series or in networks to produce a ‘nanofactory’ for the synthesis of complex chiral molecules using multi-enzyme cascade reactions.

In our design, the three modules of each nanomachine were encoded by a single gene for production in *E. coli* as a single protein with a short spacer (2-20 amino acids, Online methods) separating each module. A modified cofactor was designed that could be conjugated to the spacer between the catalytic and cofactor recycling modules. We used a maleimide-functionalized polyethylene glycol (PEG) for the flexible linker to allow movement of the modified cofactor between active sites. *In silico* modelling suggested that a chain length of twenty-four ethylene glycol units was long enough to allow ingress into both active sites. The amino acid spacer that separated the catalytic and cofactor recycling modules contained a single solvent exposed cysteine residue, which provided an accessible thiol group with which to tether the maleimide-functionalized PEGylated cofactor (Figure 1).

Assembling the nanomachines

For the prototype nanofactory we selected D-fagomine synthesis – coupling three nanomachines in series to convert glycerol (**1**) and 3-aminopropanal (**3**) into a chiral drug precursor (Figure 2). Total synthesis of this anti-diabetic piperidine iminosugar using non-biological catalysts is challenging, due to the complexity conferred by its two stereocenters, and eight possible diastereomers, with even recent advances only resulting in yields up to 65% of each diastereomer¹⁶. In our nanofactory (a cascade of nanomachines), glycerol is converted to dihydroxyacetone phosphate (DHAP) (**4**) by regiospecific phosphorylation and oxidation, *via* ATP and NAD⁺-dependent steps, respectively. A subsequent aldolase-catalyzed stereoselective aldol addition with 3-aminopropanal yields (3*S*,4*R*)-

amino-3,4-dihydroxy-2-oxyhexyl phosphate (3S,4R-ADHOP), which can be dephosphorylated with phosphorylase and cyclized to form D-fagomine¹⁷ (6). For the purposes of purification, we elected to use the carboxybenzyl (Cbz)-protected derivative of 3-aminopropanal, yielding N-Cbz-3S,4R-ADHOP (5).

Prior comparison of enzymes that could be used for the first two steps of the model synthesis¹⁸ had suggested that the most suitable enzymes for glycerol phosphorylation were a *Thermococcus kodakarensis* glycerol kinase (GlpK_{TK}) and a *Mycobacterium smegmatis* acetate kinase (AceK_{MS}). For the NAD⁺-dependent production of DHAP from glycerol-3-phosphate (G3P), *E. coli* glycerol-3-phosphate dehydrogenase (G3PD_{EC}) and the water-forming NADH oxidase from *Clostridium aminovalericum* (NOX_{CA}) were selected. The third reaction step is a cofactor-independent aldolase-catalyzed aldol addition. A monomeric fructose aldolase (FruA) homolog from *Staphylococcus carnosus* was selected from a panel of five potential aldolases. Each of the enzymes incorporated into the nanomachine fusion proteins were selected for their compatibility in batch reactions¹⁸, high catalytic rates, relatively simple quaternary structures and thermostability (Supplementary Table 2).

For the conjugation module, we used a serine hydrolase enzyme coupled with a suicide inhibitor (trifluoroketone, TFK) that forms a site-specific and stable covalent bond between the inhibitor and the catalytic serine residue¹⁹. Esterase E2 from *Alicyclobacillus acidocaldarius* (E2_{AA})²⁰ was selected for the serine hydrolase component as a highly stable, soluble, monomeric protein (Supplementary Table 2).

The genes encoding GlpK_{TK} and AceK_{MS} were fused, such that GlpK_{TK} formed the N-terminus of the resultant protein and AceK_{MS} formed the C-terminus (Fig. 2). The two modules were separated by a nineteen amino acid unstructured amino acid linker, containing a single, solvent-accessible cysteine residue that was used subsequently as the attachment point for the maleimide functionalized PEG₂₄-ATP ([GSS]₃C[GSS]₃). A similar gene fusion was constructed used G3PD_{EC} and NOX_{CA}, producing a protein in which G3PD_{EC} formed the N-terminus and NOX_{CA} formed the C-terminus. The fused proteins retained or in some cases improved their original catalytic functions (Table 1), albeit some loss of activity (both K_M and k_{cat}) was incurred for AceK_{MS} and G3PD_{EC}. The thermal stability of each of the fused enzymes appeared to be independent of one another i.e. protein unfolding of the component modules of each fusion are independent events (Supplementary Table 2).

The gene encoding the conjugation module (E2_{AA}) was fused with both the *glpK_{TK}-aceK_{MS}* and *g3pD_{EC}-nox_{CA}* such that it formed the C-terminus of the encoded proteins (i.e., GlpK_{TK}-AceK_{MS}-E2_{AA} and G3PD_{EC}-NOX_{CA}-E2_{AA}). Addition of the conjugation module had little effect on the kinetic performance or thermal stabilities of the other modules of each nanomachine (Table 1 & Supplementary Table 1). The

conjugation module was highly efficient (86-98% immobilization efficiency), and the immobilized enzymes retained their activity. This immobilization technique has the potential for broad applicability to other biocatalytic systems.

The cofactors were modified (Online methods) by functionalization of the C6-adenine-amine of ADP (7) or NAD⁺ (12) to which a modified PEG₂₄ was added (Fig. 1; Supplementary Scheme 1). The PEG₂₄ linker included an *N*-hydroxysuccinimide ester that allowed reaction with the modified cofactor and a maleimide group for conjugation with the fusion proteins. Conjugation of MAL-PEG₂₄-2AE-ADP (11) and MAL-PEG₂₄-2AE-NAD⁺ (13) to the nanomachines yielded enzymes that were active in batch reactions without the addition of exogenous cofactor, with catalytic constants equivalent or superior to individual enzyme components (Table 1; Supplementary Figure 3). Mass spectrometry of cofactor-conjugated proteolyzed nanomachines indicated that the cysteine in the linker between the catalytic and cofactor recycling modules reacted preferentially with the PEG₂₄-maleimide modified cofactors (Supplementary Figure 4). Between 80-100% of the target cysteine residue was conjugated with the modified cofactor for both nanomachines.

Function of Nanofactory

The nanomachines were immobilized on TFK-activated agarose beads at densities of 1.6, 1.0 and 1.0 milligrams protein per gram wet beads for the phosphorylation, oxidation and aldolase nanomachines, respectively, and packed into glass columns to produce three nanomachine packed bed reactor columns: a phosphorylation column (23.1 mL packed volume), an oxidation column (25.7 mL packed volume) and an aldol addition column (17.7 mL packed volume) (Figure 2).

Individual performance data for each nanomachine reactor (Figure 3) revealed that the maximum space time yields obtained ranged from ~11 mg L⁻¹ h⁻¹ mg⁻¹ (mg product per mg protein per liter per hour) for the oxidation reactor to ~70 mg L⁻¹ h⁻¹ mg⁻¹ for the phosphorylation reactor, with the aldol addition reactor yielding ~30 mg L⁻¹ h⁻¹ mg⁻¹. This is consistent with the expected yields based on k_{cat}/K_M values of the loaded enzymes (Table 1), e.g., for the phosphorylation reactor, 36.9 mg protein per column (2.7 nmol tethered biocatalysts) yielded 2.6 g product per litre (6.6 mM) per hour, equivalent to the expected 1,399 nmol per nmol of enzyme per second.

As reported elsewhere, when the glycerol-3-phosphate oxidation reaction and aldolase reaction were run in batch, yields were limited by product inhibition and substrate: product equilibrium, with substrate conversion of 88% and 63% respectively^{18, 21, 22}. In our reactors, the phosphorylation and oxidation reactions were run to completion (i.e., complete 100% substrate conversion). It is likely that

running the system as a continuous flow reaction prevented the build-up of reaction products and so mitigated both product inhibition and equilibrium control, resulting in the high yields observed in our reactors.

The turnover numbers for the cofactors exceeded 10,000 (~11,000 for the NAD⁺-dependant oxidation reactor and ~17,000 for the ATP-dependant phosphorylation reactor; Figure 3a). In each case the reactions stopped because of the inactivation of one of the modules (AceK_{MS} for the phosphotransfer reactor; NOX_{Ca} for the oxidation reactor) rather than the loss of cofactor. It is reasonable to assume that the turnover numbers would be higher if the enzymes were modified for greater stability, a relatively facile exercise with modern enzyme engineering approaches^{23, 24}.

The three reactors were then combined in series (Figure 2b), with glycerol fed to the first reactor (the phosphorylation reactor) and a feed of Cbz-protected aldehyde entering the system between the oxidation and aldol addition reactors, to yield a three component 'nanofactory' for the production of Cbz-protected chiral sugar phosphates from glycerol. When run at 0.3 mL per minute, over 80% of glycerol was converted to enantiomerically pure *N*-Cbz-3S,4R-ADHOP in a single passage through the reactor (the product was confirmed by HPLC, LCMS and ¹H NMR analysis; Supplementary Figure 6). The percent conversion dropped to 40% at higher flow rates (1.0 mL.min⁻¹), albeit this could be improved through reactor engineering (longer columns, greater biocatalyst loading, multiple passages through the reactor, *etc.*).

Conclusions

We have developed and successfully implemented a general chemo-genetic protein engineering strategy that enables cofactor-dependent, continuous-flow biocatalysis *via* the use of nanomachines: single molecule multi-enzyme biocatalysts that retain and recycle their cofactors. The engineered biocatalysts were used to construct a three step continuous-flow reactor system (a 'nanofactory') that performed well, with superior yields of D-fagomine precursor compared to chemical syntheses¹⁶, as well as high space-time yields and total turnover numbers for the catalysts and cofactors. Additionally, use of the biocatalysts in a continuous-flow system appears to have mitigated production inhibition and equilibrium control of yield, allowing very high substrate conversion.

We have used sugar analog synthesis as a model for our prototype 'nanofactory'; however, we believe that this approach is generalizable because of the modular design principles used in the design of both the 'nanomachines' and the 'nanofactories'. For the nanomachines, we envision a small library of conjugation and cofactor recycling modules that could be used in conjunction with a larger library of catalysis modules to provide access to a wide range of reactions. For example, whilst we have chosen

to demonstrate stereoselective aldol addition with the fructose-1,6-biphosphate aldolase FruA, use of the three other classes of DHAP-dependant aldolases (fuculose-1-phosphate FucA, rhamnulose-1-phosphate aldolase RhuA, tagatose-1,6-biphosphate aldolase TagA) ²² for the aldol addition reactor could be employed to generate all four ADHOP diastereomers with simple flow-path changes. The molecular modularity of the nanomachines is mirrored in the flow reactor design, providing a flexible platform for building complex, multistep biochemical pathways with both serial and parallel reactor compartments that could be extended into the development of artificial metabolic networks.

Acknowledgements

We would like to acknowledge the Science and Industry Endowment Fund (SIEF) for funding this work. We would like to thank Drs Matthew Wilding (Australian National University) and John Oakeshott (CSIRO) for their constructive comments during the preparation of this manuscript.

Author Contributions

CH, CS, CW, NT, JS, GS, GC conceived and designed the study. CH, JS, CW, NF, QI, AN, AF, TN, CN-J performed experiments. CH, CW, JS, AF, AN, TN, QI, CN-J analyzed data and AW performed computational modelling analysis. CH, CW, AN, JS, NF, TN and CS wrote the paper.

Competing Interests Statement

The authors have submitted a PCT Patent Application (WO 2017_011870_A1) based on the research results reported in this paper.

References:

1. Turner, N.J. & O'Reilly, E. Biocatalytic retrosynthesis. *Nature Chemical Biology* **9**, 285-288 (2013).
2. Wells, A. & Meyer, H.-P. Biocatalysis as a Strategic Green Technology for the Chemical Industry. *ChemCatChem* **6**, 918-920 (2014).
3. Gandomkar, S., Żądło-Dobrowolska, A. & Kroutil, W. Extending Designed Linear Biocatalytic Cascades for Organic Synthesis. *ChemCatChem* **11**, 225-243 (2019).

- 208 4. Tamborini, L., Fernandes, P., Paradisi, F. & Molinari, F. Flow Bioreactors as Complementary
209 Tools for Biocatalytic Process Intensification. *Trends in Biotechnology* (2017).
- 210 5. López-Gallego, F., Jackson, E. & Betancor, L. Heterogeneous Systems Biocatalysis: The Path to
211 the Fabrication of Self-Sufficient Artificial Metabolic Cells. *Chemistry – A European Journal* **23**,
212 17841-17849 (2017).
- 213 6. Britton, J., Majumdar, S. & Weiss, G.A. Continuous flow biocatalysis. *Chemical Society Reviews*
214 (2018).
- 215 7. Zhang, Y.-H.P., Sun, J. & Ma, Y. Biomanufacturing: history and perspective. *Journal of Industrial*
216 *Microbiology & Biotechnology*, 1-12 (2016).
- 217 8. Santacoloma, P.A. & Woodley, J.M. in *Cascade Biocatalysis* 231-248 (Wiley-VCH Verlag GmbH
218 & Co. KGaA, 2014).
- 219 9. Weiser, D. et al. in *Biocatalysis: An Industrial Perspective* 397-430 (The Royal Society of
220 Chemistry, 2018).
- 221 10. Thompson, M.P., Peñafiel, I., Cosgrove, S.C. & Turner, N.J. Biocatalysis Using Immobilized
222 Enzymes in Continuous Flow for the Synthesis of Fine Chemicals. *Organic Process Research &*
223 *Development* **23**, 9-18 (2019).
- 224 11. Dudley, Q.M., Karim, A.S. & Jewett, M.C. Cell-free metabolic engineering: Biomanufacturing
225 beyond the cell. *Biotechnology Journal* **10**, 69-82 (2015).
- 226 12. Keatinge-Clay, A.T. Stereocontrol within polyketide assembly lines. *Nat. Prod. Rep.* **33**, 141-
227 149 (2016).
- 228 13. Dutta, S. et al. Structure of a modular polyketide synthase. *Nature* **510**, 512-517 (2014).
- 229 14. Nguyen, C. et al. Trapping the dynamic acyl carrier protein in fatty acid biosynthesis. *Nature*
230 **505**, 427-431 (2014).
- 231 15. Cronan, J.E., Zhao, X. & Jiang, Y.F. in *Advances in Microbial Physiology*, Vol 50, Vol. 50. (ed.
232 R.K. Poole) 103-146 (2005).
- 233 16. Davies, S.G., Fletcher, A.M., Kennedy, M.S., Roberts, P.M. & Thomson, J.E. Asymmetric
234 synthesis of d-fagomine and its diastereoisomers. *Tetrahedron* **74**, 7261-7271 (2018).
- 235 17. Castillo, J.A. et al. Fructose-6-phosphate Aldolase in Organic Synthesis: Preparation of d-
236 Fagomine, N-Alkylated Derivatives, and Preliminary Biological Assays. *Organic Letters* **8**, 6067-
237 6070 (2006).
- 238 18. Hartley, C.J. et al. Sugar analog synthesis by in vitro biocatalytic cascade: A comparison of
239 alternative enzyme complements for dihydroxyacetone phosphate production as a precursor
240 to rare chiral sugar synthesis. *Plos One* **12** (2017).
- 241 19. Minařík, A. et al. Ligand-Directed Immobilization of Proteins through an Esterase 2 Fusion Tag
242 Studied by Atomic Force Microscopy. *ChemBioChem* **9**, 124-130 (2008).
- 243 20. Huang, Y., Humenik, M. & Sprinzl, M. Esterase 2 from *Alicyclobacillus acidocaldarius* as a
244 reporter and affinity tag for expression and single step purification of polypeptides. *Protein*
245 *Expression and Purification* **54**, 94-100 (2007).
- 246 21. Wang, W., Liu, M., You, C., Li, Z. & Zhang, Y.-H.P. ATP-free biosynthesis of a high-energy
247 phosphate metabolite fructose 1,6-diphosphate by *in vitro* metabolic engineering. *Metabolic*
248 *Engineering* **42**, 168-174 (2017).
- 249 22. Schumperli, M., Pellaux, R. & Panke, S. Chemical and enzymatic routes to dihydroxyacetone
250 phosphate. *Appl Microbiol Biotechnol* **75**, 33-45 (2007).
- 251 23. Jemli, S., Ayadi-Zouari, D., Hlima, H.B. & Bejar, S. Biocatalysts: application and engineering for
252 industrial purposes. *Crit. Rev. Biotechnol.* **36**, 246-258 (2016).
- 253 24. Modarres, H.P., Mofrad, M.R. & Sanati-Nezhad, A. Protein thermostability engineering. *RSC*
254 *Advances* **6**, 115252-115270 (2016).
- 255 25. Hartley, C.J. et al. Sugar analog synthesis by in vitro biocatalytic cascade: A comparison of
256 alternative enzyme complements for dihydroxyacetone phosphate production as a precursor
257 to rare chiral sugar synthesis. *PLOS ONE* **12**, e0184183 (2017).

26. Peat, T.S. et al. Cyanuric acid hydrolase: evolutionary innovation by structural concatenation. *Molecular microbiology* **88**, 1149-1163 (2013).
27. Koga, Y. et al. Thermostable glycerol kinase from a hyperthermophilic archaeon: gene cloning and characterization of the recombinant enzyme. *Protein Engineering* **11**, 1219-1227 (1998).
28. Aceti, D.J. & Ferry, J.G. Purification and characterization of acetate kinase from acetate-grown *Methanosarcina thermophila*. Evidence for regulation of synthesis. *Journal of Biological Chemistry* **263**, 15444-15448 (1988).
29. Kawasaki, S., Ishikura, J., Chiba, D., Nishino, T. & Niimura, Y. Purification and characterization of an H₂O-forming NADH oxidase from *Clostridium aminovalericum*: existence of an oxygen-detoxifying enzyme in an obligate anaerobic bacteria. *Archives of Microbiology* **181**, 324-330 (2004).
30. Brockamp, H.P. & Kula, M.R. Purification and characterization of a class I fructose 1,6-bisphosphate aldolase from *Staphylococcus carnosus*. *Applied Microbiology and Biotechnology* **34**, 287-291 (1990).
31. Manco, G. et al. Overexpression and properties of a new thermophilic and thermostable esterase from *Bacillus acidocaldarius* with sequence similarity to hormone-sensitive lipase subfamily. *The Biochemical journal* **332** (Pt 1), 203-212 (1998).
32. Prieto-Blanco, M.C., Iglesias, M.P., López-Mahía, P., Lorenzo, S.M. & Rodríguez, D.P. Simultaneous determination of carbonyl compounds and polycyclic aromatic hydrocarbons in atmospheric particulate matter by liquid chromatography–diode array detection–fluorescence detection. *Talanta* **80**, 2083-2092 (2010).

Fig. 1. Nanomachine design. Each nanomachine comprises a genetically encoded multi-enzyme fusion protein capable of retaining and recycling a tethered cofactor. The nanomachine contains three protein domains: a cofactor-dependant catalytic enzyme domain (purple), a cofactor-recycling domain (pink) with short amino acid spacer regions between these domains (see Online Methods for details). A cofactor that has been modified by amine activation to allow for linker installation (A) is tethered to the protein through maleimide: thiol conjugation *via* a solvent exposed cysteine located in the spacer region between the catalysis and recycling domains (B). The esterase conjugation domain (orange) allows immobilization of the nanomachine to a surface by the formation of a covalent bond between a surface attached trifluoroketone (C) and the active site serine of the esterase (D).

Figure 2. Nanofactory design for the conversion of glycerol to a chiral D-fagomine precursor. a, Composition of the three nanomachines each comprising a cofactor-dependant catalytic enzyme domain (purple), a cofactor-recycling domain (pink) and the conjugation domain (orange), with amino acid spacer regions between these domains (green). **b,** Corresponding three part nanofactory and associated biotransformations (phosphotransfer, oxidation and aldol addition) for D-fagomine synthesis. Enzyme name abbreviations are as defined in the text.

a

Nanomachine	Flow rate (mL min ⁻¹)	R _t (min)	Product Yield (mmol)	Total Turnover Number (cofactor)	Space Time Yield (g L ⁻¹ hr ⁻¹ g ⁻¹)
Phosphotransfer Reactor GlpK _{TK} -ATP _{1eth} -AceK _{MS} -Est2 _{Δa}	0.25	84.8	1.17	16848	69.95
Oxidation Reactor G3PD _{EC} -NAD _{1eth} -NOX _{CS} -Est2 _{Δa}	0.25	113.2	0.95	10839	10.75
Aldol Addition Reactor FruA _{SC} -Est2 _{Δa}	0.1	177	4.67	NA	28.58

b

Figure 3. Functional analysis of the three-step nanofactory for the synthesis of D-fagomine from glycerol. **a**, Product yield, cofactor total turnover numbers and space-time yield metrics for each nanomachine reactor. **b**, The nanofactory maintained continuous product yields of between 85-90% conversion of glycerol to *N*-Cbz-3S,4R-amino-3,4-dihydroxy-2-oxyhexyl phosphate (*N*-Cbz-3S,4R-ADHOP) for more than 7 h.

Table 1. Steady-state kinetic data for the enzymes comprising each nanomachine.

	K_M (μM)	K_M (μM)	k_{cat} (s^{-1})	k_{cat}/K_M ($\text{s}^{-1} \cdot \text{M}^{-1}$)
	Cofactor	Substrate		
Glycerol phosphorylation				
GlpK _{TK}	111 ± 12	15 ± 2	940 ± 8	6.1 × 10 ⁷
GlpK _{TK} -AceK _{MS}	123 ± 21	15 ± 4	1,125 ± 115	7.7 × 10 ⁷
GlpK _{TK} -AceK _{MS} -Est2 _{Aa}	115 ± 19	16 ± 4	1,399 ± 54	8.6 × 10 ⁷
GlpK _{TK} -ATP _{teth} -AceK _{MS} -Est2 _{Aa}	ND	16 ± 2	1,408 ± 95	8.8 × 10 ⁷
Acetate dephosphorylation (ADP phosphorylation)				
AceK _{MS}	113 ± 9	390 ± 8	1,103 ± 126	2.8 × 10 ⁶
GlpK _{TK} -AceK _{MS}	424 ± 35	1,400 ± 126	759 ± 53	5.4 × 10 ⁵
GlpK _{TK} -AceK _{MS} -Est2 _{Aa}	398 ± 29	1,197 ± 114	1,084 ± 27	9.1 × 10 ⁵
GlpK _{TK} -ATP _{teth} -AceK _{MS} -Est2 _{Aa}	ND	ND	ND	ND
Glycerol-3-phosphate oxidation				
G3PD _{EC}	158 ± 24	59 ± 4	85 ± 11	1.4 × 10 ⁶
G3PD _{EC} -NOX _{Ca}	176 ± 12	369 ± 17	7 ± 0.7	1.8 × 10 ⁴
G3PD _{EC} -NOX _{Ca} -Est2 _{Aa}	164 ± 10	659 ± 47	7 ± 0.6	1.1 × 10 ⁴
G3PD _{EC} -NAD _{teth} -NOX _{Ca} -Est2 _{Aa}	ND	659 ± 47	9 ± 0.6	1.4 × 10 ⁴
Oxygen reduction (NADH oxidation)				
Nox _{Ca}	258 ± 21	ND	1,252 ± 182	4.9 × 10 ⁶
G3PD _{EC} -NOX _{Ca}	276 ± 9	ND	1,714 ± 252	6.2 × 10 ⁶
G3PD _{EC} -NOX _{Ca} -Est2 _{Aa}	266 ± 15	ND	1,224 ± 114	4.6 × 10 ⁶
G3PD _{EC} -NAD _{teth} -NOX _{Ca} -Est2 _{Aa}	ND	ND	ND	ND
Aldol addition			DHAP	
FruA _{Sc}	NA	500 ± 80	16 ± 2	3.2 × 10 ⁴
FruA _{Sc} -Est2 _{Aa}	NA	70 ± 11	9 ± 1	1.3 × 10 ⁵
Esterase¹				
Est2 _{Aa}	NA	180 ± 40	153 ± 12	8.3 × 10 ⁵
GlpK _{TK} -AceK _{MS} -Est2 _{Aa}	NA	165 ± 18	149 ± 16	8.8 × 10 ⁵
G3PD _{EC} -NOX _{Ca} -Est2 _{Aa}	NA	152 ± 28	159 ± 11	9.0 × 10 ⁵
FruA _{Sc} -Est2 _{Aa}	NA	100 ± 10	165 ± 18	1.7 × 10 ⁶

¹ (*p*-nitrophenyl acetate as substrate). ND- not determined. NA- not applicable.

ON-LINE METHODS

General

Unless otherwise stated in the text, all chemicals were purchased from Sigma-Aldrich (Merck, Australia). For the flow reactors, regulated flow rates and mixing was provided by a modified Biologic DuoFlow system with a Biologic Fraction Collector (Biorad laboratories Inc., USA) for collection of samples. Biologic DuoFlow software v 5.10 Build 2 (Biorad Laboratories Inc., USA) was used to program and control the system, as per manufacturer's instructions. All restriction enzymes and T4 DNA ligase enzymes used for DNA manipulation were purchased from New England Bioabas (NEB, USA). All PEG compounds were purchased from Quanta BioDesign Ltd (Plain City, OH, USA) and used as received. All other reagents and solvents were obtained from Sigma-Aldrich (Merck), Acros Organics or TCI Chemicals and used as-purchased. Nuclear Magnetic resonance (NMR) spectra were recorded with a Bruker Avance 400 MHz spectrometer in the deuterated solvents as specified. Chemical shifts (δ) were calibrated against residual solvent peaks and are quoted in ppm relative to TMS.

Unless otherwise specified in the text, analytical high-performance liquid chromatography (aHPLC) was performed with a Waters Alliance e2695 Separations Module equipped with Waters 2998 PDA and Acquity QDa detectors, using a Waters XBridge BEH C18 column, 130 Å, 3.5 μ m, 2.1 x 50 mm. The following buffer system and gradients were applied: Milli-Q water (Merk Millipore) with 0.1% formic acid (Buffer A) and CH₃CN with 0.1% formic acid (Buffer B), with a gradient of 0-90% Buffer B unless otherwise specified.

Semi-preparative reversed-phase high performance liquid chromatography (RP-pHPLC) was undertaken using a Shimadzu SPD-10A UV-Vis detector with UV detection at λ 260 nm. The system was equipped with a Shimadzu 322 pump and Gilson 255 Liquid Handler and set at a flow rate of 10 mL min⁻¹. Peak separation was achieved using a Vydac 218TP1022 C18, 10 μ m, 22 x 250 mm column. Solvent gradients used Milli-Q water with 0.1% TFA (Buffer A) and acetonitrile with 0.1% TFA (Buffer B), with a gradient of 0-70% Buffer B unless otherwise specified.

DNA manipulation

The pAF1 vector that encodes the DHAP-dependent fructose-1,6-biphosphate aldolase from *Staphylococcus carnosus* was a gift from Dr A. Frazer (University of Manchester, Manchester, UK). For all other constructs, the gene of interest was sourced as described previously²⁵, codon-optimized for expression in *E. coli* and synthesized by GeneArt (ThermoFisher Scientific, Germany), then cloned into

pETCC2²⁶ (a modified version of pET14b, Novagen) using *Nde* I and *Bam* HI or *Eco* RI sites, to create an in-frame *N*-terminal hexa-histidine tag. Genes encoding fusions between the catalytic and cofactor-recycling domains (GlpK_{TK}-AceK_{MS} and G3PD_{EC}-NOX_{Ca}) were synthesized. Two versions of the synthetic genes were made. In the first version, a single open reading frame containing both domains, separated by a linker and terminating in a STOP codon were synthesized, and included a 5' *Nde* I site and 3' *Bam* HI site for cloning. The second version differed in that the stop codon was omitted and a 3' *Sph* I site was included to allow construction of the fusions that included the conjugation domain. The versions with a STOP codon were cloned into pETCC2 for expression and purification of GlpK_{TK}-AceK_{MS} and G3PD_{EC}-NOX_{Ca}, whilst the *Nde* I-*Sph* I versions were subcloned into a prepared pETCC2 backbone containing the esterase *e2*_{Aa} gene to create a genetic fusion via the *Sph* I site, with a short Gly-Ser repeat spacer. This yielded genes encoding the GlpK_{TK}-AceK_{MS}-E2_{Aa} and G3PD_{EC}-NOX_{Ca}-Est2_{Aa} nanomachines. A similar strategy was used to fuse *fruA*_{Sc} with *e2*_{Aa} via the *Sph* I site yielding a construct encoding FruA_{Sc}-Est2_{Aa} (Supplementary Figure 1). The final insertion fragments used for each of the nanomachines are depicted in Supplementary Figure 1. All constructs were confirmed by DNA sequencing (Macrogen, S. Korea).

Supplementary Figure 1. DNA insertion regions for each of the nanomachine expression constructs encoding GlpK_{TK}-AceK_{MS}-E2Aa (a), G3PDEc-NOXCa-Est2Aa (b) and FruA_{Sc}-Est2Aa (c), combining each multienzyme fusion as a single ORF for insertion into pETCC2 via the *Nde* 1-*Bam* H1 sites to create an in-frame 5'-hexahistidine tag.

Engineered Fusion Protein Sequences

The hexaHIS-tagged individual and fusion protein sequences used in this study are listed below, with linker regions between the protein domains highlighted in bold and underlined, and the cysteine required for tethering modified cofactor highlighted in red bold font:

G3PD_{Ec}

MNQRNASMTVIGAGSYGTALAITLARNGHEVVLWGHDP~~EH~~IATLERDRCNAAFLPDVPFPD~~TL~~HL~~ES~~D
LATALAASRNILVVVPSHVFG~~EV~~LRQIKPLMRPDARLVWATKGLEAETGRLLQDVAREALGDQIPLAV
ISGPTFAKELAAGLPTAISLASTDQTFADDLQQLLHCGKSFRVYSNPDFIGVQLGGAVKNVIAIGAGM
SDGIGFGANARTALITRGLAEMSRLGAALGADPATFMGMAGLGD~~LV~~LTCTDNQSRNRRFGMMLGQGMD
VQSAQEKIGQVVEGYRNTKEVRELAHRFGVEMPITEEIIYQVLYCGKNAREAAALTLLGRARKDERS~~SS~~H*

Nox_{Ca}

MGSSHHHHHHSSGLVPRGSHMKIVVIGCTHAGTAAVKTILKENPEAEITIFERN~~DN~~ISFLSCGIALYV
GGVVKDPAGLFYSNPEELSKMGANVKIKHN~~VKS~~IDTKSKKVIAEDMNTGEEIEVS~~YD~~KL~~VNT~~TGSWPI
IPPIPGIESKNILLCKNYDQANV~~IIR~~QTKDAKKIVIVGGGYIGIELVEAFQKSGKQV~~TL~~IDGLDRILN
KYLDKEFTDILED~~DL~~KKNGINLALDQCVKSFKANENGEVTSVETTKGEYEADMVILCVGFRPNNELLK
GKVDMLPND~~AI~~IIVDEYMRTSDPDIFAAGDSCAVHYNPNNGNYAYIPLATNAVRMGMLIGKNISTPKVKY
RGTQSTSGLNLF~~GY~~NIGSTGVTVSGAPQIGLN~~VRS~~VIVKDN~~YR~~PEFMPTNEEIIIMQLVYE~~VG~~TNRIVG
GQVMSKYDITQSANTLSLAIQNKMTIEDLAYVDFFFQPHFDRPWN~~YL~~NILGLAALEQ~~EG~~L*

GlpK_{Tk}

MGSSHHHHHHSSGLVPRGSHMEKFVLSLDEGTTSARAIIFDRESNIHGIGQYEF~~PQ~~HYPRPGWVEHNP
EEIWDAQLRAIKDAIQSARIEPNQIAAIGVTNQRETTLVWDKDGKPLYN~~AI~~VWQCRRTAEMVEEIKRE
YGTMIKEKTGLVPDAYFSASKLWLLDNVPGLREKA~~EK~~GEVMFGTVDTFLIYRLTGEHVTDYSNASRT
MLFNIKKLDWDDELLELFDIPESVLPEVRESSEVYGYTKKELLGAEIPVSGDAGDQQAALFGQA~~AFE~~A
GMVKATYGTGSFILVNTDKMVL~~YSD~~NLLTTIAWGLNGRVSYALEGSIFVTGA~~AV~~QWLRDGIKIIKHAS
ETEELATKLESNEG~~VY~~FVPAFVGLGAPYWDQFARGIIIGITRGTGREHLARATLEAIA~~YL~~TRDVVDEM
EKL~~VQ~~IKELRVDGGATANDFLMQFQADILNRKVIRPVVKET~~TAL~~GAA~~YL~~AGLAVDYWADTREIAELWK
AERIFEPKMDEKTRERLYKGWKEAVKRAMGWAKV~~VDS~~AKSN*

AceK_{Ms}

MGSSHHHHHHSSGLVPRGSHMTVLV~~VNS~~GSSSLKYAVVRPASGEFLADGIIIEIGSGAVPDHDAALRA
AFDELA~~AA~~AGLHLEDLDLKAVGHRMVHGKTFYKPSVVDDELIAKARELSPLAPLHNPPA~~IK~~GIEVARK
LLPDLPHIAVFD~~TAF~~FHDL~~PAP~~ASTYAIDRELAETWHIKRYGFHGT~~SHE~~YVSQQA~~AI~~FLDRPLESLN~~Q~~
IVLHLGN~~AS~~ASAVAGGKAVDTS~~MGL~~TPMEGLVMGTRSGDIDPGVIMYLWRTAGMSVDDIESMLNRRS
GVLGLGGASDFRKLRELIESGDEHAKLAYDVYI~~HRL~~RKYIGAYMAVLGR~~TD~~VISFTAGVGENVPPVRR
DALAGLGGLGIEIDDALNSAKSDEPRLISTPDSRVTVLVVPTNEELAIARACVGVV*

408 **GlpK_{Tk}-AceK_Ms**

409 MGSSHHHHHHSSGLVPRGSHMEKFVLSLDEGTT SARAI IFDRESNIHGIGQYEFQHYPRPGWVEHNP
 410 EEIWD AQLRAIKDAIQSARIEPNQIAAIGVTNQRETTLVWDKDGKPLYNAIVWQCRRTAEMVEEIKRE
 411 YGTMIKEKTGLVPDAYFSASKLKWLLDNVPGLREKAEKGEVMFGTVDTFLIYRLTGEHVTDYSNASRT
 412 MLFNIKKLDWDDELLELFDIPESVLPEVRESSEVYGYTKKELLGAEIPVSGDAGDQQAALFGQA AFEA
 413 GMVKATYGTGSFILVNTDKMVLYSNLLTTIAWGLNGRVSYALEGSIFVTGAAVQWLRDGIKIIKHAS
 414 ETEELATKLESNEG VYFVP AFVGLGAPYWDQFARGIIIGITRGTGREHLARATLEAIAYLTRDVVDEM
 415 EKL VQIKELRVDGGATANDFLMQFQADILNRKVIRPVVKETTALGAAYLAGLAVDYWADTREIAELWK
 416 AERIFEPKMDEKTRERLYKGWKEAVKRAMGWAKVVD SAKSN GSSGSSGSSCGSSGSSGSSMTVLVVNS
 417 GSSSLKYAVVRPASGEFLADGIIIEIGSGAVPDHDAALRAAFDELAAGLHLEDLDLKAVGHRMVHGG
 418 KTFYKPSVVDELI AKARELSPLAPLHNPPAIKGIEVARKLLPDLPHIAVFDTAFFHDL P APASTYAI
 419 DRELAETWHIKRYGFHGTSH EYVSQQA AIFLDRPLESLNQIVLHLNGASASAVAGGKA VDTSMGLTP
 420 MEG LVMGTRSGDIDPGVIMYLWRTAGMSVDDIESMLNRRSGVLGLGGASDFRKLRELIESGDEHAKLA
 421 YDVYIHR LRKYIGAYMAVLGR TDVISFTAGVGENVPVRRDALAGLGGLGIEIDDALNSAKSDEPRLI
 422 STPDSRVTVLVVPTNEELAIARACVGVV*

423 **G3PD_{Ec}-NOX_{Ca}**

424 MGSSHHHHHHSSGLVPRGSHMNQRNASMTVIGAGSYGTALAITLARNGHEVVLWGHDP EHIATLERDR
 425 CNA AFLPDVPFPD TLHLESD LATALAASRNILVVVPSHVFG EVLRQIKPLMRPDARLVWATKGLEAET
 426 GRLLQDVAREALGDQIPLAVISGPTFAKEL AAGLP TAISLASTDQTFADDLQQLLHCGKSFRVYSNPD
 427 FIGVQLGGAVKNVIAIGAGMSDGIGFGANARTALITRGLAEMSRLGAALGADPATFMGMAGLGDVLVT
 428 CTDNQSRNRRFGMMLGQGMDVQSAQEKIGQVVEGYRNTKEVRELAHRFGVEMPITEE IYQVLYCGKNA
 429 REAALTLLGRARKDERS SH GSSGSSGSSGSSGSSGSSMKIVVIGCTHAGTA AVKTI LKENPEAEITIF
 430 ERNDNISFLSCGIALYVGGVVKDPAGLFYSNPEELSKMGANVKIKHNVKSIDTKSKKVIAEDMNTGEE
 431 IEVSYDKLVNTTGSWPIIPPIPGIESKNILLCKNYDQANV IIRQTKDAKKIVIVGGGYIGIELVEAFQ
 432 KSGKQVTLIDGLDRILNKYLDKEFTDILED DLKKNGINLALDQCVKSFKANENGEVTSVETTKGEYEA
 433 DMVILCVGFRPNNEL LKGKVDMLPNDAIIVDEYMRTSDPDIFAAGDSCAVHYNPNNGNYAYIPLATNAV
 434 RMGMLIGKNISTPKVKYRG TQSTSGNLNFGYNIGSTGVTVSGAPQIGLNVRSVIVKDN YRPEFMPTNE
 435 EIIMQLVYEVGTNRIVGGQVMSKYDITQSANTLSLAIQNKMTIEDLAYVDFFFQPHFDRPWN YLNLG
 436 LAALEQEGL*

437 **GlpK_{Tk}-AceK_Ms-E2_{Aa}**

438 MGSSHHHHHHSSGLVPRGSHMEKFVLSLDEGTT SARAI IFDRESNIHGIGQYEFQHYPRPGWVEHNP
 439 EEIWD AQLRAIKDAIQSARIEPNQIAAIGVTNQRETTLVWDKDGKPLYNAIVWQCRRTAEMVEEIKRE
 440 YGTMIKEKTGLVPDAYFSASKLKWLLDNVPGLREKAEKGEVMFGTVDTFLIYRLTGEHVTDYSNASRT
 441 MLFNIKKLDWDDELLELFDIPESVLPEVRESSEVYGYTKKELLGAEIPVSGDAGDQQAALFGQA AFEA
 442 GMVKATYGTGSFILVNTDKMVLYSNLLTTIAWGLNGRVSYALEGSIFVTGAAVQWLRDGIKIIKHAS

443 ETEELATKLESNEGVIYFVPAFVGLGAPYWDQFARGIIIGITRGTGREHLARATLEAIAYLTRDVVDEM
 444 EKLIVQIKELRVDGGATANDFLMQFQADILNRKVIRPVVKETTALGAAYLAGLAVDYWADTREIAELWK
 445 AERIFEPKMDEKTRERLYKGWKEAVKRAMGWAKVVDSSAKSNGSSGSSGSSCGSSGSSGSSMTVLVVNS
 446 GSSSLKYAVVRPASGEFLADGIIIEIGSGAVPDHDAALRAAFDELAAGLHLEDLDLKAVGHRMVHGG
 447 KTFYKPSVVDELIKARELSPLAPLHNPPAIKGIEVARKLLPDLPHIAVFDTAFFHDLPAFASTYAI
 448 DRELAETWHIKRYGFHGTSHEYVSQQAAIFLDRPLESLNQIVLHLGNGASASAVAGGKAVDTSMGLTP
 449 MEGLVMGTRSGDIDPGVIMYLWRTAGMSVDDIESMLNRRSGVLGLGGASDFRKLRELIESGDEHAKLA
 450 YDVYIHLRKYIGAYMAVLGRDVISFTAGVGENVPPVRRDALAGLGGLGIEIDDALNSAKSDEPRLI
 451 STPDSRVTVLVVPTNEELAIARACVGVVGTGSSGSSGSSGSSMPLDPVIQQVLDQLNRMPAPDYKHLIS
 452 AQQFRSQQSLFPPVKKEPVAEVREFDMDLPGRTLKVRMYRPEGVEPPYPALVYYHGGGWVGDLETHD
 453 PVCRLAKDGRAVVSVDYRLAPEHKFPAAVEDAYDALQWIAERAADFHLDPARIAVGGDSAGGNLAA
 454 VTSILAKERGGPALAFQLLIYPSTGYDPAHPPASIEENAEGYLLTGMMWLWFRDQYLNLSLEELTHPWF
 455 SPVLYPDLGLPPAYIATAQYDPLRDVGKLYAEALNKAGVKVEIENFEDLIHGFAQFYSLSPGATKAL
 456 VRIAEKLRDALA*

457

458 **G3PD_{Ec}-NOX_{Ca}-Est2_{Aa}**

459 MGSSHHHHHHSSGLVPRGSHMNQRNASMTVIGAGSYGTALAITLARNGHEVVLWGHDPHEIATLERDR
 460 CNAFLPDVPFPDTHLESDLATALAASRNILVVVPSHVFGVLRQIKPLMRPDARLVWATKGLEAET
 461 GRLLQDVAREALGDQIPLAVISGPTFAKELAAGLPTAISLASTDQTFADDLQQLLHCGKSFRVYSNPD
 462 FIGVQLGGAVKNVIAIGAGMSDGIGFGANARTALITRGLAEMSRLGAALGADPATFMGMAGLDLVLT
 463 CTDNQSRNRRFGMMLGQGMVDVQSAQEKIGQVVEGYRNTKEVRELAHRFGVEMPITEEIIYQVLYCGKNA
 464 REAALTLLGRARKDERSSSHGTSGSSGSSCGSSGSSGSSMKIVVIGCTHAGTAAVKTILKENPEAEITI
 465 FERNDNISFLSCGIALYVGGVVKDPAGLFYSNPEELSKMGANVKIKHNVKSIDTKSKKVIAEDMNTGE
 466 EIEVSYDKLVNTTGSWPIIPPIPIGIESKNILLCKNYDQANVIIRQTKDAKKIVIVGGGYIGIELVEAF
 467 QKSGKQVTLIDGLDRILNKYLDKEFTDILEDLDKKNGINLALDQCVKSFKANENGEVTSVETTKGEYE
 468 ADMVILCVGFRPNNELLLKGKVDMLPNDAIIVDEYMRTSDPDIFAAGDSCAVHYNPNNGNYAYIPLATNA
 469 VRMGMLIGKNISTPKVKYRGTSGLNLFYNGISTGVTVSGAPQIGLNVRSVIVKDNYPFEMPTN
 470 EEIIMQLVYEVGTNRIVGGQVMSKYDITQSANTLSLAIQNKMTIEDLAYVDFFFQPHFDRPWNYNLIL
 471 GLAALEQEGLGSSMPLDPVIQQVLDQLNRMPAPDYKHLISAQQFRSQQSLFPPVKKEPVAEVREFDMDL
 472 PGRTLKVRMYRPEGVEPPYPALVYYHGGGWVGDLETHDPVCRVLAKDGRAVVSVDYRLAPEHKFPAA
 473 AVEDAYDALQWIAERAADFHLDPARIAVGGDSAGGNLAAVTSILAKERGGPALAFQLLIYPSTGYDPA
 474 HPPASIEENAEGYLLTGMMWLWFRDQYLNLSLEELTHPWFSPVLYPDLGLPPAYIATAQYDPLRDVGK
 475 LYAEALNKAGVKVEIENFEDLIHGFAQFYSLSPGATKALVRIAEKLRDALA*

476

477 **FruA_{Sc}-Est2_{Aa}**

478 MGSSHHHHHHSSGLVPRGSHMKILAITSCPNGIAHTYMAQEKLEQAAKEMGVDIKVETQGGVGAENVL
 479 TAKEIREADGIIIAADRQVDLSRFNGKRLINENVREGIHHPKELIQRIIDQNAPIHHEKGASDNDSE

EEEEKSGVQM VYQHL MNGVSFMV PFIVVGGLLIAIALTLGGEPSAKGLVIPDDSFWKSIEKIGALSFS
 FMVPILAGYIAYS IADKPGLVPGMIGGAIAADGSFYGSEAGAGFLGGIVAGFLAGYIAKWIKNVKVPK
 AMAPIMPIIIIIPIISSVIVGLIFIFLIGAPISGIFTALTGWLKG MQGANIVVLALIIGAMIAFDMGGP
 VNKVAF LFSGSALIAEGNYAVMGMVAVAVCTPPIGLGLATFLQKGKFNNSEQEMGKASFTMGLFGITEG
 AIPFAAQDPLRIIPANMIGAMVA AVIAALGGVGDRVAHGGPIVAVLGGIQHVLWFFVAVIIGSLITMF
 TVLLFKKNTPVAVLEGE GVVEDGIGDGQSHSNNQVAESRTENNEQKDDDSVFHKDLIELRQESMQRDN
 AIDQ LLEKLKDAGYIESLDKVKEAVLQREAE STTAIGMNVAIPHAKSDAVKQPAVAVLQDKQGI EWES
 LDGTSPKIVFLIVVPNN SNDTHLKLQLSRALMDDETREN LINATTKDEIYNILKMI GS MPLDPV IQ
 QVLDQLNRMPAPDYKHL SAQQFRSQQLSFPVKKEPVAEVREFDMDLPGR TLKVRMYRPEGVEPPYPA
 LVYYHGGGWVVG DLETHDPVCRVLAKDGRAVVFSVDYRLAPEHKFPAAVEDAYDALQWIAERAADFHL
 DPARIAVGGDSAGGNLAAVTSILAKERGGPALAFQLLIYPSTGYDPAHPPASIEENAEGYLLTGMMML
 WFRDQYLNSLEELTHPWFSPVLYPDL SGLPPAYIATAQYDPLRDVGKLYAEALNKAGVKVEIENFEDL
 IHGFAQFYSLSPGATKALVRIA EKLRDALA*

Protein Expression and Purification

Expression of individual enzymes and bi-enzymatic fusion proteins.

The expression plasmids outlined above were used to transform *E. coli* BL21 DE3 Star (Invitrogen, ThermoFisher Scientific, USA), using Luria agar containing 100 µg mL⁻¹ ampicillin as a selective growth medium. Cells were cultured overnight in Luria broth containing 100 µg mL⁻¹ ampicillin at 37 °C and shaken at 200 rpm, then induced for 2, 4, 6 and 24 h with either arabinose or isopropyl β-D-1-thiogalactopyranoside (IPTG) at 0.2 M and 1 mM final concentration, respectively (see Supplementary Table 1 for details). Cultures were then harvested, by centrifugation at 8000 g, resuspended in one tenth culture volume of resuspension buffer (50 mM Tris-Cl, 250 mM NaCl, pH 7.5) and lysed with Bugbuster™ (Novagen). Protein expression was analyzed by SDS-PAGE separation (4-12% Bolt Bis-Tris Plus Polyacrylamide Gel with MES SDS running buffer (Invitrogen, USA) and visualized with NuBlue (Novagen). The optimal expression time (Supplementary Table 1) was selected and large scale expression cultures of 1-2 L prepared in the same way as above except that cells were lysed by passage through an EmulsiFlex-C5 cell homogenizer (Avestin) at 20,000 psi, 4 °C and cellular debris removed by centrifugation (40,000 x g, 15 min, 4 °C). Protein was first purified from cell free lysates by IMAC purification of HIS-tagged protein by elution with resuspension buffer (50 mM Tris-Cl, 250 mM NaCl, pH 7.5) containing increasing concentration of imidazole from NiNTA-sepharose (Hi5 HIS-TRAP, GE Healthcare). The desired protein fractions were then pooled and further purified using a Superdex 200 size exclusion column (GE Healthcare). Pooled fractions were then concentrated and stored at 4 °C, or -80 °C, as required.

Supplementary Table 1. Optimal recombinant expression conditions for the individual enzymes and multi-enzyme fusions comprising each nanomachine.

Enzyme	Construct	Expression Vector	Host Cells	Inducer; Temperature (°C) and Time [h]
Phosphotransfer Nanomachine Proteins				
GlpK _{TK}	pCJH1	pETCC2	<i>E.coli</i> BL21DE3 Star (Invitrogen)	1mM IPTG; 37°C, 18h
AceK _{MS}	pCJH2	pDEST17 (Invitrogen)	<i>E.coli</i> BL21AI (Invitrogen)	20mM arabinose 15°C, 18h
GlpK _{TK} -AceK _{MS}	pCJH3	pETCC2	<i>E.coli</i> BL21DE3 Star (Invitrogen)	1mM IPTG; 37°C, 18h
GlpK _{TK} -AceK _{MS} -Est2 _{Aa}	pCJH4	pETCC2	<i>E.coli</i> BL21DE3 Star (Invitrogen)	1mM IPTG; 37°C, 18h
Oxidation Nanomachine Proteins				
G3PD _{Ec}	pCJH5	pDEST17 (Invitrogen)	<i>E.coli</i> BL21AI (Invitrogen)	20mM arabinose 25°C, 18h
NOX _{Ca}	pCJH6	pETCC2	<i>E.coli</i> BL21DE3 Star (Invitrogen)	1mM IPTG; 37°C, 18h
G3PD _{Ec} -NOX _{Ca}	pCJH7	pETCC2	<i>E.coli</i> BL21DE3 Star (Invitrogen)	1mM IPTG; 25°C, 18h
G3PD _{Ec} -NOX _{Ca} -Est2 _{Aa}	pCJH8	pETCC2	<i>E.coli</i> BL21DE3 Star (Invitrogen)	1mM IPTG; 25°C, 18h
Aldol addition Nanomachine Proteins				
FruA _{Sc}	pAF1	pRSET-A (Invitrogen)	<i>E.coli</i> BL21DE3	1mM IPTG; 15°C, 18h
FruA _{Sc} -Est2 _{Aa}	pCJH9	pETCC2	<i>E.coli</i> BL21DE3 Star (Invitrogen)	1mM IPTG; 15°C, 18h
Esterase Conjugation Domain Protein				
Est2 _{Aa}	pCJH10	pETCC2	<i>E.coli</i> BL21DE3 Star (Invitrogen)	1mM IPTG; 37°C, 18h

Each of the purified individual and bi-enzymatic fusion proteins were then characterised in terms of catalytic activity (Table 1), thermostability and oligomeric structure (Supplementary Table 2) to ensure suitability for incorporation into the final nanomachine constructs with the esterase conjugation domain, utilising the enzymatic activity assays and analytical methods outlined below. Further specific details regarding the expression and purification of the final three nanomachine multi-enzyme fusion proteins used to construct the nanofactory is given below.

Supplementary Table 2. Biochemical characterization of the individual enzymes and multi-enzyme fusions comprising each nanomachine.

	Optimal Reaction pH (pH range)	T_{50}^* (°C)	Oligomeric Structure	k_{cat}/K_M ($s^{-1} M^{-1}$)	Reference
Glycerol phosphorylation					
GlpK _{TK}	8.0 (6.5-9.5)	> 100	monomer	6.1×10^7	²⁷ ; This study
GlpK _{TK} -AceK _{MS}		58	dimer	7.7×10^7	This study
GlpK _{TK} -AceK _{MS} -Est2 _{Aa}		59	monomer/hexamer	8.6×10^7	This study
Acetate dephosphorylation (ADP phosphorylation)					
AceK _{MS}	7.4 (6.0-8.5)	52	homodimer	2.8×10^6	²⁸ ; This study
GlpK _{TK} -AceK _{MS}		50	dimer	5.4×10^5	This study
GlpK _{TK} -AceK _{MS} -Est2 _{Aa}		63	monomer/hexamer	9.1×10^5	This study
Glycerol-3-phosphate oxidation					
G3PD _{EC}	9.0 (8.0-9.5)	51	monomer	1.4×10^6	¹⁸ ; This study
G3PD _{EC} -NOX _{Ca}		37	dimer	1.8×10^4	This study
G3PD _{EC} -NOX _{Ca} -Est2 _{Aa}		45	dimer	1.1×10^4	This study
Oxygen reduction (NADH oxidation)					
NOX _{Ca}	7.0 (7.0-9.0)	37	homodimer	4.9×10^6	²⁹ ; This study
G3PD _{EC} -NOX _{Ca}		37	dimer	6.2×10^6	This study
G3PD _{EC} -NOX _{Ca} -Est2 _{Aa}		37	dimer	4.6×10^6	This study
Aldol addition					
FruA _{Sc}	6.5-9.0	> 95	monomer	3.2×10^4	³⁰
FruA _{Sc} -Est2 _{Aa}		81	monomer	1.3×10^5	This study
Esterase¹					
Est2 _{Aa}	7.1 (5.5-8.0)	80	monomer	8.3×10^5	³¹ ; This study

* T_{50} the temperature at which, after 30 min of incubation, 50% of the initial enzyme activity remains. The T_{50} values are the averages of at least three independent assays. Standard deviations were below 1.0 °C in all cases. pH optima did not vary between individual and fusion enzymes.

Expression of GlpK_{TK}-AceK_{MS}-E2_{Aa}.

The expression of GlpK_{TK}-AceK_{MS}-E2_{Aa} in *E. coli* BL21 DE3 Star (Invitrogen, ThermoFisher Scientific, USA) cells transformed with the plasmid pETCC2- GlpK_{TK}-AceK_{MS}-E2_{Aa} (pCJH4; Supplementary Table 1) was examined after induction at 15 °C for 18 h with 1 mM IPTG as inducer, and the oligomeric state related to fusion protein activity, using glycerol kinase activity as a proxy for all three activities (Supplementary Figure 2). Although all three oligomeric states isolated by gel filtration purification (Superdex 150 gel filtration column, GE Healthcare, after pooling HIS-tagged purification pools from a 5 mL HisTrap FF

column, GE Healthcare) demonstrated glycerol kinase activity, the maximum specific activity per milligram of protein was retained in the “monomeric-dimeric” fraction (Supplementary Figure 2). For subsequent experiments, the monomeric-dimeric fraction was isolated.

For large scale preparation of GlpK_{TK}-AceK_{MS}-E2_{Aa} fusion protein pCH4 was transformed into *E. coli* BL21DE3 Star cells. Cells were cultured in Luria broth overnight at 37 °C with shaking at 200 rpm, diluted to OD_{600nm} 0.7 in Luria broth and induced at 15 °C for 18 h with arabinose and IPTG (20 mM and 1 mM final concentration, respectively) and then harvested, washed in one tenth volume resuspension buffer (50 mM Tris-Cl, 250 mM NaCl, pH 7.5) and cell pellets stored at -20 °C. Cell paste (8 g) was resuspended in 200 mL 50 mM Tris, 300 mM NaCl pH 8 containing 0.5 mg mL⁻¹ lysozyme (Sigma–Aldrich), 2 mM PMSF (Sigma–Aldrich), four EDTA-Free Complete Protease inhibitor tablets (Roche) and 1000 Units Benzonase (Merck Millipore). Following resuspension, the cells were ruptured by passage three times through an EmulsiFlex-C5 cell homogenizer (Avestin) at 15,000 psi at 4 °C and cellular debris removed by centrifugation (40,000 x g, 15 min, 4 °C). The lysate was filtered (0.45 µm) and one quarter applied to a 5 mL HisTrap FF column (GE Healthcare) equilibrated in 50 mM Tris, 300 mM NaCl pH 8 containing 0.1 mM tris-(2-carboxyethyl)phosphine (TCEP). The column was washed with 40 mM imidazole in the same buffer then the bound protein eluted with 300 mM imidazole in the same buffer. The eluted protein was analyzed by gel filtration on a Superdex 200 1030 gel filtration column (GE Healthcare) equilibrated with phosphate buffered saline with the absorbance of the eluted protein monitored at 280 nm and the esterase activity in the eluted fractions determined. For comparison, 0.5 mL of crude lysate was also subjected to gel filtration analysis, with monitoring at 280 nm and analysis of esterase activity in the fractions.

Expression and purification of G3PD_{Ec}-NOX_{Ca}-Est2_{Aa}.

Briefly, *E.coli* BL21 DE3 Star (Invitrogen) cells expressing G3PD_{Ec}-NOX_{Ca}-Est2_{Aa} (pCJH8, Supplementary Table 1) were cultured in an XRS 20 bioreactor (Pall Corporation, USA) using a 2 litre volume of M9 minimal medium, with 1% (w/v) ammonium sulphate and 1% (w/v) glucose as nitrogen and carbon source respectively and supplemented with 100 µg mL⁻¹ ampicillin. After initial growth at 37 °C, the temperature was reduced to 25 °C prior to induction, when the OD_{600nm} reached 2.2. The optical density of the culture at induction was OD_{600nm} 2.9 and 1.6 mL of 20% arabinose and IPTG to 1 mM were added to induce. The glucose feed was started 7 h post-induction to maintain 1% glucose and cells were harvested 22 h post-induction, when OD_{600nm} was 21.6.

Cell paste (2 g) was resuspended in 50 mL 50 mM Tris, 300 mM NaCl pH 8 containing 0.1 mM Tris-(2-carboxyethyl)phosphine (TCEP; Sigma-Aldrich), 0.5 mg mL⁻¹ lysozyme (Sigma-Aldrich), 2 mM phenylmethane sulfonyl fluoride (PMSF; Sigma-Aldrich), one EDTA-Free Complete Protease inhibitor tablet (Roche) and 250 Units Benzonase (Merck Millipore). Following resuspension, the cells were ruptured by passage three times through an EmulsiFlex-C5 cell homogenizer (Avestin) at 15,000 psi at 4 °C and cellular debris removed by centrifugation (40,000 x g, 15 min, 4 °C). The lysate was filtered (0.45 µm) and applied to a 5 mL HisTrap FF column (GE Healthcare) equilibrated in 50 mM Tris, 300 mM NaCl pH 8 containing 0.1 mM TCEP. The column was washed with 40 mM imidazole in the same buffer then the bound protein eluted with 300 mM imidazole in the same buffer. The eluted protein was subjected to gel filtration on a Superdex 200 gel filtration column (GE Healthcare) equilibrated with 50 mM citrate, 200 mM NaCl pH 6 containing 1 mM TCEP with the absorbance of the eluted protein monitored at 280 and 450 nm. Fractions eluting from 158 – 192 mL were pooled and concentrated to 0.94 mg mL⁻¹.

G3PD_{EC}-NOX_{Ca}-Est2_{Aa} eluted in a broad peak from the gel filtration column, with some protein eluting in the void volume (Supplementary Figure 2). The final pool was > 95% pure as estimated by SDS-PAGE and was found to have specific activities of 16 U mg⁻¹ for esterase and 31 U mg⁻¹ for NADH oxidase.

Expression and purification of FruA_{Sc}-Est2_{Aa}.

FruA_{Sc} was selected as the preferred aldolase for the nanofactory based on its enantioselectivity (3S, 4R-ADHOP), oligomeric structure, stability, catalytic rate (Supplementary Table 2) and previous success using this enzyme in multi-enzyme cascades to produce similar chiral sugars¹⁸.

For the preparation of the aldol addition nanomachine, we constructed genetic fusions between FruA_{Sc} and E2_{Aa} as illustrated in Supplementary Figure 1. Purified FruA_{Sc}-E2_{Aa} was obtained by expression and purification from *E. coli* BL21 DE3 Star cells (Invitrogen, Thermofisher Scientific). Briefly, a synthetic gene encoding FruA_{Sc}-E2_{Aa} was transferred into pETCC2 (pCJH10, Supplementary Table 1) and used to transform *E. coli* BL21DE3 Star (Invitrogen) cells. Cells were cultured in Luria broth overnight at 37 °C with shaking at 200 rpm, diluted to OD_{600nm} 0.7 in Luria broth and induced for 18 h with arabinose and IPTG (20 mM and 1 mM final concentration, respectively). The cells were then harvested, washed in one tenth volume resuspension buffer (50 mM Tris-Cl, 250 mM NaCl, pH 7.5) and cell pellets stored at -20 °C. Cell paste (8 g) was resuspended in 200 mL 50 mM Tris, 300 mM NaCl pH 8 containing, 0.5 mg mL⁻¹ lysozyme (Sigma-Aldrich), 2 mM PMSF (Sigma-Aldrich), four EDTA-Free Complete Protease Inhibitor tablets (Roche) and 1000 Units Benzonase (Merck Millipore). Following resuspension, the cells were ruptured by passage three times through an EmulsiFlex-C5 cell homogenizer (Avestin) at 15,000 psi and 4 °C and cellular debris removed by centrifugation (40,000 x g, 15 min, 4 °C). The lysate

was filtered (0.45 μ m) and applied to a 5 mL HisTrap FF column (GE Healthcare) equilibrated in 50 mM Tris, 300 mM NaCl pH 8 containing 0.1 mM TCEP. The column was washed with 40 mM imidazole in the same buffer then the bound protein eluted with 300 mM imidazole in the same buffer. The eluted protein was analyzed by gel filtration on a Superdex 200/1030 gel filtration column (GE Healthcare) equilibrated with phosphate buffered saline with the absorbance of the eluted protein monitored at 280 nm (Supplementary Figure 2) and the esterase activity in the eluted fractions determined.

Supplementary Figure 2. Expression and purification of nanomachine fusion proteins. **a**, Size exclusion fractionation of HIS-tag purified recombinant GlpK_{TK}-AceK_{MS}-E2_{AA} multi-enzyme fusion protein was used to estimate oligomeric state and associated specific activity after induction with 1 mM IPTG at 15 °C for 24 h. **b**, Size exclusion fractionation of HIS-tag purified recombinant G3PD_{EC}-NOX_{CA}-Est2_{AA}. Fractions from 158 – 192 mL were pooled to avoid higher MW aggregate. **c**, SDS-PAGE analysis of G3PD_{EC}-NOX_{CA}-Est2_{AA} purification. Lane 1 BenchmarkTM protein molecular weight standard (Invitrogen), Lane 2 whole cells, Lane 3 pellet after centrifugation of lysate, Lane 4 lysate, Lane 5 HisTrap unbound, Lane 6 40 mM imidazole wash, Lane 7 300 mM imidazole elution, Lane 8 gel filtration pool. **d**, Size exclusion fractionation profile of HIS-tag purified recombinant FruA_{SC}-Est2_{AA}. **e**, SDS-PAGE analysis of FruA_{SC}-Est2_{AA} purification. Lane 1 Fraction 1B1, Lanes 2-15 fractions 1C1 to 2A3, Lane 16 DualTM Protein molecular weight standard (NEB).

Cofactor modification

Synthesis of N⁶-2AE-ADP.

Adenosine-5'-phosphate sodium salt, ADP.xNa, (0.5 g, 1.13 mmol) was dissolved in distilled deionised (DI) water (1.5 mL) and ethyleneimine (160 μ L) was added very slowly. During the addition of the ethyleneimine, the pH was carefully adjusted with perchloric acid to keep it within the pH range of

2.0-4.0. The pH at the end was left at 3.2. The reaction was stirred at room temperature for ~50 h. The solvent was then evaporated in a fume-hood under a stream of nitrogen. The crude residue was dissolved in DI water (10 mL) and the pH adjusted to 5.6 by the addition of lithium hydroxide (LiOH; saturated aq. solution) and heated at 35 °C for 80 h. The solution was lyophilized to yield crude *N*⁶-2AE-ADP (Supplementary Scheme 1).

Synthesis of MAL-PEG₂₄-2AE-ADP.

Crude *N*⁶-2AE-ADP DIPEA salt (100 mg, crude estimate equivalent to about 13.7 mmol pure 2AE-ADP) was dissolved in 50% acetonitrile/phosphate buffered saline pH 7.0 (3.0 mL) and a solution of MAL-PEG₂₄-NHS (43.0 mg) was added and stirred at room temperature overnight (Supplementary Scheme 1). The mixture was purified by pHPLC and lyophilized to yield pure MAL-PEG₂₄-2AE-ADP (12.2 mg).

Synthesis of *N*⁶-2AE-NAD⁺.

To a solution of β-nicotinamide adenine dinucleotide hydrate, NAD⁺, (1.0 g, 1.51 mmol) dissolved in 2 mL deionized water was added dropwise ethyleneimine (4.25 mmol) with the solution maintained at a pH of 3.2 with the addition of 70% perchloric acid. The reaction mixture was stirred at room temperature for 50 h with the pH maintained from 2-3, before the addition of 1.75 mL deionized water to solubilise precipitate. The product was precipitated by the addition of ice-cold ethanol and the precipitate washed with ethanol. The resulting mix of *N*¹-2AE-NAD⁺ and NAD⁺ was dissolved in water (10 mL) and adjusted to pH 6.5 with 0.1 M LiOH. The solution was stirred at 50 °C for 7 h with the pH maintained at 6.5 before being lyophilized to yield the product, as a mixture of *N*⁶-2AE-NAD⁺ and NAD⁺ (Supplementary Scheme 1).

Synthesis of MAL-PEG₂₄-2AE-NAD⁺.

To a stirred solution of *N*⁶-2AE-NAD⁺/NAD⁺ (14.7 mg mix, approximately 0.0104 mmol *N*⁶-2AE-NAD⁺) in phosphate buffered saline (PBS; pH 7.4, 1.0 mL) was added a solution of MAL-PEG₂₄-NHS (17.4 mg, 0.0124 mmol) in PBS (1 mL). The solution was stirred at room temperature overnight (Supplementary Scheme 1). The mixture was analyzed by HPLC (0→50% CH₃CN + 0.1% TFA over 18 min). Rt 17.8 min ESI+ found 662.62 (M/3, calcd 662.65) and 993.42 (M/2, calcd 993.98). The mixture was purified by preparative HPLC and fractions at Rt 17.8 min combined and lyophilized to yield pure MAL-PEG₂₄-2AE-NAD⁺ (5.4 mg, 26%).

Supplementary Scheme 1. Synthesis of modified cofactors for tethering to nanomachine fusion proteins. a, Scheme for synthesis of MAL-PEG_n-2AE-ADP (**11**) from ADP (**7**). **b**, Scheme for synthetic route to prepare MAL-PEG_n-2AE-NAD⁺ (**13**) from NAD⁺ (**12**).

Cofactor attachment

Tethering of MAL-PEG₂₄-2AE-ADP to Glp_{TK}-AceK_{M5}-Est2_{Aa} in solution.

IMAC purified Glp_{TK}-AceK_{M5}-Est2_{Aa} was found to elute as high molecular weight protein and in PBS (Supplementary Figure 2). The IMAC purified protein was treated with TCEP (0.1 mM) then reacted with 10 equivalents of MAL-PEG₂₄-2AE-ADP without removal of the TCEP and washed with PBS. The tethered 2AE-ADP-PEG₂₄-MAL-Glp_{TK}-AceK_{M5}-Est2_{Aa} was found to convert 10 mM glycerol and 10 mM acetyl phosphate to glycerol-3-phosphate with high efficiency (Supplementary Figure 3a).

Tethering of MAL-PEG₂₄-2AE-NAD⁺ to G3PD_{Ec}-NOX_{Ca}-Est2_{Aa} in solution.

G3PD_{Ec}-NOX_{Ca}-Est2_{Aa} was desalted into PBS containing 0 mM, 0.1 mM or 1 mM TCEP and reacted with 1–200 equivalents of MAL-PEG₂₄-2AE-NAD⁺. The reaction mixtures were analyzed by SDS-PAGE and the conjugate from one condition (0.1 mM TCEP, 200 equivalents TCEP) analyzed by mass spectrometry. The tethered 2AE-NAD⁺-PEG₂₄-MAL-G3PD_{Ec}-NOX_{Ca}-Est2_{Aa} was found to convert 10 mM glycerol-3-phosphate and to DHAP with high efficiency (Supplementary Figure 3b).

a

b

Supplementary Figure 3. Functional tethering of modified cofactors MAL-PEG₂₄-2AE-ADP (a) and MAL-PEG₂₄-2AE-NAD⁺ (b) to nanomachine fusion proteins. **a**, Glycerolkinase activity with and without the addition of 100 μ M ATP catalyzed by either 2AE-ADP-PEG₂₄-MAL-GlpK_{TK}-AceK_{M5}-E2_{Aa} or by GlpK_{TK}-AceK_{M5}-E2_{Aa} was then coupled with glycerol-3-phosphate dehydrogenase activity (G3PD_{Ec}-NOX_{Ca}-E2_{Aa}) and aldolase activity (FruA_{Sc} with glyceraldehyde-3-phosphate as added donor substrate) to demonstrate the production of fructose-1,6-biphosphate from 10 mM glycerol using 2AE-ADP-PEG₂₄-MAL-GlpK_{TK}-AceK_{M5}-E2_{Aa}. A scheme of the three step reaction involved is illustrated beneath the graph. **b**, Glycerol-3-phosphate dehydrogenase activity (DHAP production rate) using 10 mM glycerol-3-phosphate with and without the addition of 100 μ M NAD⁺ catalyzed by 2AE-NAD⁺-PEG₂₄-MAL-G3PD_{Ec}-NOX_{Ca}-E2_{Aa} created under different reducing and tethering conditions: untethered control G3PD_{Ec}-NOX_{Ca}-E2_{Aa} (A), 1 mM TCEP and 1 equivalent MAL-PEG₂₄-2AE-NAD⁺ (B), 0.1 mM TCEP and 1 equivalent MAL-PEG₂₄-2AE-NAD⁺ (C), no TCEP and 1 equivalent MAL-PEG₂₄-2AE-NAD⁺ (D), 1 mM TCEP and 5 equivalent MAL-PEG₂₄-2AE-NAD⁺ (E). All reactions were conducted for 30 minutes at 37 °C, and products analysed by LCMS as described in analytical methods.

Accurate mass determination of MAL-PEG₂₄-2AE-NAD⁺ tethered to G3PD_{Ec}-NOX_{Ca}-Est2_{Aa} by LC-MS proteomics.

The accurate mass of G3PD_{Ec}-NAD_{teth}-NOX_{Ca}-Est2_{Aa} conjugates was determined by denaturing liquid chromatography–mass spectrometry (LC-MS). Protein samples were spiked with formic acid (FA) to a final concentration of 0.1% (v/v) and separated by reverse-phased liquid chromatography on an UltiMate 3000 RSLC nano system (ThermoFisher Scientific) fitted with a 50 x 4.6 mm, 5 μ M particle size, 300 Å pore size PLRP-S column (Agilent). Proteins were eluted at a flow of 250 μ L min⁻¹ by applying a linear 30 min gradient from 0 to 80% solvent B (mobile phase A: 0.1% (v/v) formic acid; mobile phase B: 90% (v/v) acetonitrile/0.1% (v/v) formic acid) using an Apollo II electron spray ion source coupled to a microTOF-QII mass spectrometer (Bruker). The instrument was calibrated in positive ion mode using ESI-L Low Concentration Tuning Mix (Agilent) and LC-MS raw data were processed and deconvoluted using the MaxEnt algorithm as part of Bruker Compass DataAnalysis version 4.3.

Sample preparation and peptide sequencing by nanoUPLC-MSMS

G3PD_{Ec}-NAD_{teth}-NOX_{Ca}-Est2_{Aa} protein bands were manually excised from Coomassie-stained SDS-PAGE gels and subjected to manual in-gel reduction, alkylation and tryptic digestion. All gel samples were reduced with 10 mM DTT (Sigma) for 30 min, alkylated for 30 min with 50 mM iodoacetamide (Sigma) and digested with 375 ng trypsin gold (Promega) for 16 h at 37 °C. Peptides then were separated using an UltiMate 3000 RSLC nano system (ThermoFisher Scientific), utilizing a 60 min gradient on an Acclaim Pepmap 100 column (50 cm x 75 μ m id with 3 μ m particles). High-resolution MS/MS data was obtained on an Orbitrap Fusion Lumos Mass Spectrometer operated in data-dependent mode,

automatically switching between the acquisitions of a single Orbitrap MS scan (resolution, 120,000) every 3 s and the top-20 multiply charged precursors selected for EThcD fragmentation with a resolution of 30,000 for Orbitrap MS-MS scans.

Mass spectra database searching

Orbitrap MS/MS data was searched against a focused decoy database containing G3PD_{Ec}-NOX_{Ca}-Est2_{Aa} and common contaminant protein sequences using the Byonic search engine (Protein Metrics) with tolerance of 5 ppm for precursor ions and 10 ppm for product ions. Enzyme specificity was tryptic and allowed for up to 2 missed cleavages per peptide. A Wildcard search with a range of +75 to +2200Da facilitated confident peptide identification (< 1% FDR) and spectrum counting of PEGylated cysteine residues. Variable modifications were set for NH₂-terminal acetylation or protein N-termini, oxidation of methionine or tryptophan, and carbamidomethyl modification of cysteine.

All of the cysteine containing peptides from the tryptic digest were able to be observed by mass spectrometry in the unconjugated sample, but the conjugated sample was missing the peptide corresponding to the linker cysteine, and instead peptides corresponding to the conjugated peptide were observed (Supplementary Figure 4).

Supplementary Figure 4: Confirmation of functional Mal-PEG₂₄-2AE-NAD⁺ linkage to G3PD_{Ec}-NOX_{Ca}-Est2_{Aa} residue Cys369. **a**, Cartoon of the chemical structure of MAL-PEG₂₄-2AE-NAD⁺ conjugated to G3PD_{Ec}-NOX_{Ca}-Est2_{Aa} residue Cys369 of tryptic peptide SSHGTSGSSGSSCGSSGSSGSSMK highlighting different MSMS fragment ions (peptide b-ions, blue; peptide y-ions, MAL-PEG₂₄-2AE-NAD⁺ CID ions, gold). **b**, Annotated LC-MSMS evidence spectrum for a high-scoring R.SSHGTSGSSGSSC[+1685]GSSGSSGSSM[+32]K.I peptide highlighting peptide b- and y-ions (blue, red) as well as the observed masses and chemical structures of matching MAL-PEG₂₄-2AE-NAD⁺ fragments. The observed +1685Da mass modification and fragmentation pattern is consistent with G3PD_{Ec}-NOX_{Ca}-Est2_{Aa} Cys396 being tethered to a functional MAL-PEG₂₄-2AE-NAD⁺ linker.

Nanomachine immobilization onto agarose beads and nanomachine conjugation to modified cofactors.

Synthesis of thiohexyltrifluoroketone (hTFK).

1,6-Hexanedithiol (601 mg, 0.612 mL, 4 mmol) was added to a stirred mixture of NaHCO_3 (4 mmol) in anhydrous dichloromethane (8 mL) under a nitrogen atmosphere. Bromotrifluoroacetone (0.415 mL,

0.4 mmol) was then added dropwise. Reaction was monitored by TLC. The reaction mixture was stirred under N₂ for 5 days at room temperature and then poured into 50 mL water. After extraction with ether (3 x 30 mL), the organic solvent was dried (MgSO₄) and the solvent removed under reduced pressure. Thiohexyltrifluoroketone was characterised by LC-MS; aHPLC (20 – 80% gradient MeCN into H₂O, 0.1% TFA) gave a single peak at 6.6 min (λ = 214 nm), > 90% purity, ESI (negative scan mode) found 259.16 amu; calculated MW = 260.33. hTFK could be used directly in loading the DVS-modified beads.

Synthesis of hTFK-vinylsulfone activated beads.

4% crosslinked agarose (Sephacrose CL-4B, GE Healthcare) was functionalized by treatment with divinylsulfone (DVS) to yield the vinylsulfone decorated agarose as an aqueous slurry with vinyl sulfones at approximately 1 mmol mL⁻¹ of slurry. To 500 g of damp drained Sepharose CL-4B was added 500 mL of 0.5 M Na₂CO₃ (pH 12) and 5000 μ L divinylsulfone. The resulting suspension was stirred gently for 70 min at room temperature before being washed extensively with water. The solution was stored as a 1:1 w/v slurry in 50% ethanol/water. This activated DVS-agarose was then reacted with thiohexyltrifluoroketone (hTFK) at approximately 5 molar percent ratio for between 6 h and overnight before capping all remaining vinyl sulfone functionalities with 2-mercaptoethanol. Saturated NaHCO₃ solution (20 mL), and thiohexyl trifluoroketone (1.2 mL ethanol solution containing 26 mg of compound, 0.1 mmol, 5% loading) were added to the divinyl sulfone resin (200 mL, 16-20 mmol, 50% slurry in 1:1 ethanol/water) and stirred at room temperature for 2 h; excessive reactive sites were blocked by the addition of beta-mercaptoethanol (2.8 mL, 40 mmol) and washed with 50% ethanol/water until no smell was evident. The hTFK-loaded agarose gel obtained was filtered, washed and stored as a 1:1 slurry in 50% ethanol/water for further use. The synthesis scheme is summarized below (Supplementary Scheme 2).

Supplementary Scheme 2. Scheme for the preparation of hTFK decorated agarose beads via vinylsulfone activation.

Immobilization of GlpK_{TK}-AceK_{MS}-Est2_{Aa} to Sepharose-DVS-hTFK.

A lysate from 8 g GlpK_{TK}-AceK_{MS}-Est2_{Aa} cells prepared as described previously (200 mL) was added to 25 g Sepharose-DVS-hTFK, and the slurry mixed at 4 °C. The loss of esterase activity in the supernatant was monitored and after 2.5 h there was no further loss of esterase activity, and the adsorbent containing 5.2 U esterase per g beads, corresponding to an estimated 0.8 mg GlpK_{TK}-AceK_{MS}-Est2_{Aa} per g, or 6 nmol GlpK_{TK}-AceK_{MS}-Est2_{Aa} per gram, was filtered and washed.

Tethering of MAL-PEG₂₄-2AE-ADP to immobilized Sepharose-DVS-TFK-GlpK_{TK}-AceK_{MS}-Est2_{Aa}.

The Sepharose-DVS-GlpK_{TK}-AceK_{MS}-Est2_{Aa} (25 g) was incubated in Tris-buffered saline pH 7.0 containing 1 mM TCEP for 1.5 h at 4 °C before being washed with extensively degassed PBS containing 0.5 mM EDTA. An equal volume of this buffer was added to the slurry together with 0.8 μmol MAL-PEG₂₄-2AE-ADP and the mixture allowed to react for 6 h at 4 °C with mixing. The slurry was then filtered and washed with TBS.

Immobilization of G3PD_{EC}-NOX_{Ca}-Est2_{Aa} to Sepharose-DVS-hTFK.

To lysate from 10.6 g G3PDEc-NOX_{Ca}-Est2_{Aa} cell paste prepared as described for the purification of G3PD_{EC}-NOX_{Ca}-Est2_{Aa} above was added 80 g Sepharose-DVS-hTFK and the mixture stirred gently for 100 min at 4 °C. The slurry was filtered and washed with extensively degassed PBS containing 0.5 mM EDTA and 10 μM TCEP.

Tethering of MAL-PEG₂₄-2AE-NAD⁺ to immobilized Sepharose-DVS-TFK-G3PD_{EC}-NOX_{Ca}-Est2_{Aa}.

To 35 mL of the slurry was added an equal volume of this buffer together with 580 nmol MAL-PEG₂₄-2AE-NAD⁺ and the mixture allowed to react at 4 °C with mixing for 30 min before being filtered and washed with PBS containing 1 mM TCEP.

Reactor Assembly

In line with the intended modular, hierarchal organization of our nanomachine technology, we optimized each nanomachine reactor individually and then combined them into a serial multi-enzyme D-fagomine nanofactory as shown in Figure 2.

The Phosphotransfer Reactor

For the preparation of the phosphotransfer reactor (Figure 2), 40 mg of GlpK_{TK}-AceK_{MS}-Est2_{AA} protein (296 nmol) was immobilized onto 25 g of Sepharose-hexyl-DVS-TFK beads. The immobilized GlpK_{TK}-AceK_{MS}-Est2_{AA} was treated with 0.1 mM TCEP, washed with PBS containing 0.5 mM EDTA then reacted with six equivalents MAL-PEG₂₄-2AE-ADP for 6 h at 4 °C before being washed with reaction buffer (0.2 M sodium citrate buffer pH 7.9). The resultant immobilized cofactor-tethered nanomachine beads were analyzed for glycerol kinase activity in the presence and absence of ATP in batch reactions, and demonstrated to have ~30% tethering efficiency (activity without added ADP calculated as the percentage of activity with added ADP). The resultant immobilized nanomachine beads were then packed into a 25 mm*15 mm Benchmark column (Kinesis, Australia) to a packed bed volume of 21.2 mL and performance assessed in a flow reactor system.

A bioreactor packed with the immobilized GlpK_{TK}-ATP_{teth}-AceK_{MS}-Est2_{AA} nanomachine beads was found to convert 10 mM glycerol and 10 mM acetyl phosphate to G3P and acetate with approximately 60% efficiency at the optimal flow rate of 0.25 mL min⁻¹ (Supplementary Figure 5a). This resulted in a space time yield of 70 mg G3P L⁻¹ hr⁻¹ mg⁻¹ protein. The bioreactor stability was further assessed by continuing to run the phosphotransfer reactor for a total time of 870 minutes resulting in a total 14222 turnovers of the tethered cofactor (Figure 3).

The Oxidation Reactor

For the preparation of the G3PD_{EC}-NOX_{CA}-Est2_{AA} oxidation reactor (step 2 in Figure 2), 80 mg of G3PD_{EC}-NOX_{CA}-Est2_{AA} protein (647 nmol; 1260 esterase U) was immobilized onto 80 g of Sepharose-hexyl-DVS-TFK. The immobilized G3PD_{EC}-NOX_{CA}-Est2_{AA} was treated with TCEP, washed with degassed, sparged PBS containing 0.5 mM EDTA then reacted with six equivalents MAL-PEG₂₄-2AE-NAD⁺ for 6 h at 4 °C before being washed with PBS. The resultant immobilized cofactor-tethered nanomachine beads were analyzed for glycerol-3-phosphate dehydrogenase activity in the presence and absence of

NAD⁺ in batch reactions, and demonstrated to have ~ 80% tethering efficiency (activity without added NAD⁺ calculated as the percentage of activity with added NAD⁺). The resultant immobilized nanomachine beads were then packed into a 250 mm x 15 mm Benchmark column (Kinesis, Australia) to a packed bed volume of 28.3 mL and assessed in a flow reactor system.

A column packed with the adsorbent was found to convert 10 mM G3P to DHAP with about 40 – 50% efficiency at a flow rate of 0.25 mL min⁻¹ (Supplementary Figure 5b). This resulted in a space time yield of 2.60 mg DHAP L⁻¹ hr⁻¹ mg⁻¹ protein. The bioreactor stability was further assessed by continuing to run the oxidation reactor for a total time of 6000 minutes resulting in a total 1843 turnovers of the tethered cofactor (Figure 3).

The Aldol Addition Reactor

For the preparation of immobilized nanomachine beads for the aldol addition reactor, 20 mg of FruA_{Sc}-Est2_{Aa} protein was reacted with 20 g of Sepharose–hexyl-DVS-TFK beads. The resultant immobilized aldolase nanomachine beads were then packed into a 150 mm x 15 mm Benchmark column (Kinesis, Australia) to a final depth of 10 cm (17.7 mL packed bed volume) and assessed in a flow reactor system. Optimal flow rate was assessed for the aldol reactor and found to be 0.1 mL min⁻¹, with approximately 86% and 98% conversion of 5 mM *N*-Cbz-3-aminopropanal and 5 mM DHAP respectively, under these conditions (Supplementary Figure 5c).

a Phosphotransfer reactor

b Oxidation reactor

c Aldol Addition Reactor

Supplementary Figure 5. Assembly and testing of each of the nanomachine reactors used to assemble the Nanofactory. **a**, Phosphotransfer Reactor: Conversion of glycerol and acetyl phosphate (10 mM each) to G3P and acetate by immobilized GlpK_{TK}-ATP_{teth}-AceK_{MS}-Est2_{AA} in a packed bed reactor column (1.5 cm id, 12 cm) run at a flow rate of 0.25 mL min⁻¹, as determined by LCMS analysis of 5 mL fractions. **b**, Oxidation reactor: conversion of G3P to DHAP in a flow reactor. The immobilized G3PD_{EC}-NAD_{teth}-NOX_{CA}-Est2_{AA} nanomachine beads were used to prepare a packed bed reactor column (1.5 cm id x 16.5 cm). 10 mM G3P pH 8 was passed through the column at a flow rate of 0.25 mL min⁻¹ and the amount of G3P remaining and DHAP produced determined by LCMS for 5 mL fractions F1 to F10. **c**, Aldol addition reactor with Fru_{SC}-E2_{AA}: conversion of Cbz-aldehyde and DHAP into *N*-Cbz-3S,4R-ADHOP in a flow reactor. The immobilized Fru_{SC}-E2_{AA} nanomachine beads prepared in the presence of 10 μM TCEP were used to prepare a packed bed reactor column (1.5 cm id x 16.5 cm). 5 mM *N*-Cbz-3-aminopropanal and DHAP in 50 mM citrate buffer pH 7 was passed through the column at a flow rate of 0.1 mL min⁻¹ and the amount of DHAP and *N*-Cbz-3-aminopropanal remaining quantified by LCMS for 5 mL fractions F1 to F10.

Enzyme activity assays (In batch and in flow)

Glycerol kinase activity

Glycerol kinase assays were performed at room temperature in 1 mL volume with direct detection of ADP and ATP by HPLC analysis of reaction supernatant. A typical reaction contained 1 mM glycerol, 10 mM MgCl₂, 50 mM NaHCO₃ buffer pH 9.0, 1 mM ATP with approximately 2 μg mL⁻¹ enzyme (~35 nM). Kinetics were determined by varying the concentrations of ATP or glycerol whilst maintaining the other in excess, and kinetic determinants calculated using HyperTM (J.S. Easterby, Liverpool University) or GraphPad Prism (GraphPad Software Inc., USA). Substrate and cofactor concentrations ranged from 0.1 to 10 x *K_M*.

Acetate kinase activity.

Acetate kinase assays were conducted in the same manner as the glycerol kinase assays described above, replacing ATP with ADP, and glycerol with acetyl phosphate or phosphoenol pyruvate. Kinetics were determined by varying the concentrations of ADP or acetyl phosphate or phosphoenol pyruvate whilst maintaining the other components in excess, and kinetic determinants calculated using Hyper (J.S. Easterby, Liverpool University). Substrate and cofactor concentrations ranged from 0.1 to 10 x *K_M*.

Glycerol-3-phosphate dehydrogenase activity

Glycerol-3-phosphate (G3P) dehydrogenase activity was determined from the oxidation of glycerol-3-phosphate to DHAP in 50 mM sodium phosphate pH 9.0 for individual enzyme assays, or at pH 8.0 for combined multienzyme reactions, with the reaction progress followed by monitoring the production of NADH spectroscopically at 340 nm ($\epsilon_{340\text{ nm}} = 6.22\text{ mM}^{-1}\text{cm}^{-1}$), or by direct detection of both G3P

(substrate) and DHAP (product) using LCMS (see Analytical methods and Supplementary Figure 6), with one unit of glycerol-3-phosphate activity defined as the amount required to oxidize 1 μmol G3P in one minute at ambient temperature. Kinetics were determined by varying the concentration of G3P and NAD^+ from 0.1 to 10 $\times K_M$ and kinetic determinants were calculated using HyperTM (J.S. Easterby, Liverpool University) or GraphPad Prism (GraphPad Software Inc., USA).

NADH oxidase activity (untethered).

NADH oxidase activity was determined from the oxidation of 0.1 mM NADH in 50 mM sodium phosphate pH 7 containing 1 mg mL^{-1} BSA, with the loss of NADH monitored spectroscopically at 340 nm ($\epsilon_{340\text{ nm}} 6.22\text{ mM}^{-1}\text{cm}^{-1}$), with one unit of NADH oxidase activity defined as the amount required to oxidize 1 μmol NADH in one minute at ambient temperature. Kinetics were determined by varying the concentration of NADH from 0.1 to 10 $\times K_M$ and kinetic determinants were calculated using HyperTM (J.S. Easterby, Liverpool University) or GraphPad Prism (GraphPad Software Inc., USA).

Esterase activity.

Esterase activity was determined from the hydrolysis of *p*-nitrophenyl acetate (Sigma) in 50 mM sodium phosphate pH 7 containing 1 mg mL^{-1} BSA and with a typical reaction containing 0.4 mM *p*-nitrophenyl acetate. The hydrolysis of *p*-nitrophenyl acetate was determined spectroscopically by the increase in absorbance at 405 nm due to production of *p*-nitrophenol ($\epsilon_{405\text{ nm}} 18\text{ mM}^{-1}\text{cm}^{-1}$), with one unit of esterase activity defined as the amount required to hydrolyze 1 μmol *p*-nitrophenyl acetate in one minute at ambient temperature. Kinetics were determined by varying the concentration of substrate from 0.1 to 10 $\times K_M$ and kinetic determinants were calculated using HyperTM (J.S. Easterby, Liverpool University) or GraphPad Prism (GraphPad Software Inc., USA).

Analytical Methods

HPLC separation of ATP and ADP.

HPLC separation was conducted using an Agilent Eclipse XDB column (50 mm x 4.6 mm) with isocratic elution using 75% solvent A and 25% solvent B. Solvent A: 20 mM tetrabutylammonium phosphate

(TBAP) in 10 mM ammonium phosphate buffer pH 4.0; solvent B: acetonitrile. Flow rate 1 mL per minute, detection at 240 nm using diode array detector (Agilent Technologies, USA). Peaks eluted at the following retention times: ADP 1.2 min, ATP 1.8 min.

LCMS analysis of glycerol-3-phosphate (G3P), dihydroxyacetone phosphate (DHAP) and aldol products.

G3P and DHAP were separated using a modification of the method described in Prieto-Blanc *et al.*, 2010³². Chromatographic conditions were SIELC ObeliscN column (100 mm x 2.1 mm) with isocratic elution using 20% mobile phase A, 80% mobile phase B for 5 minutes. Mobile phase A: 25 mM ammonium formate pH 4.0; mobile phase B: acetonitrile. Mass spectrophotometric detection was conducted using API-ES negative mode with an Agilent 6120 Quadropole LCMS. Compounds were qualitatively detected by ion scanning in both positive and negative mode using know standards, and then quantified based on selected ion monitoring (SIM) monitoring of relevant ions. Glycerol-3-phosphate was quantified by selected ion monitoring of ion $[M]^-$ $m/z = 171.06$, DHAP quantified by selected ion monitoring of ion $[M]^-$ $m/z = 169.04$, after establishing suitable selected ions using positive and negative scanning of standards. Quantitation was based on comparison to standard calibration curves produced in the same manner. *N*-Cbz-3-aminopropanal and *N*-Cbz-3S,4R-ADHOP were detected and quantified using absorbance A_{214nm} and selected ion monitoring of ion $[M-H]^-$ $m/z = 376.09$ (*N*-Cbz-3S,4R-ADHOP) by comparison with calibration curves made using a synthesised standard (Supplementary Figure 6). The *N*-Cbz-3S,4R-ADHOP standard was synthesised from DHAP (Sigma-Aldrich) and *N*-Cbz-3-aminopropanal (Sigma-Aldrich) using enzymatic aldol addition with purified FruA_{Sc} and the resultant *N*-Cbz-3S,4R-ADHOP was purified essentially as described by Castillo and colleagues¹⁷. ¹H-NMR spectroscopy confirmed the purity of the standard (Supplementary Figure 6c) and this standard was then used to identify and quantitate the *N*-Cbz-3S,4R-ADHOP produced from the nanofactory by selected ion monitoring.

Supplementary Figure 6. HPLC and HPLC-MS traces and spectra for all components quantified to measure the conversion of glycerol and aldehydes into chiral aldol products. **a**, HPLC separation and mass spectrometry identification of glycerol-3-phosphate (G3P) and dihydroxy acetone phosphate (DHAP). The dominant selected ions identified here (m/z 171⁻ for G3P and m/z 169⁻ for DHAP) were then used for SIM analyzes of subsequent reactions. **b**, HPLC separation of *N*-Cbz-3-aminopropanal and *N*-Cbz-3*S*,4*R*-ADHOP showing absorbance A_{214nm} (upper panel) and mass spectrometry identification of *N*-Cbz-3*S*,4*R*-ADHOP (inset). **c**, the authenticity of *N*-Cbz-3*S*,4*R*-amino-3,4-dihydroxy-2-oxyhexyl phosphate (*N*-Cbz-3*S*,4*R*-ADHOP) produced by the nanofactory was confirmed by ¹H-NMR analysis of *N*-Cbz-3*S*,4*R*-ADHOP prepared by reaction of commercially available *N*-Cbz-3-aminopropanal and DHAP catalysed by FruA, and isolated by HPLC.